← Leaderboards
Nicholas Andrew Geisse
Curi Bio Inc
$11,267,464
Attributed
$11,267,464
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,267,464 · 9
By mechanism
R44$8,283,791 · 4
U44$2,086,960 · 1
R43$896,713 · 4
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Drug Development”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$256,285,510
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Klaus Romero · Critical Path Institute$88,602,036
Research focus
Drug DevelopmentPhenotypeResponseCellsPharmaceutical PreparationsPre-ClinicalIn VitroScreeningCostIn VivoFailureTechnologyValidationClinical TrialsProductionTissuesHeartCardiacDesignBaseBiomedical EngineeringNovel TherapeuticsIn Vitro ModelCell Line
Grant awards (25)
A cross-species preclinical platform to enhance the translation of new medicines$1,149,771
R44 · FY2025 · TR · contact PI
High-Throughput NMJ Assay for Botox Potency Screening$901,175
U44 · FY2025 · TR · contact PI
High-Throughput NMJ Assay for Botox Potency Screening$910,019
U44 · FY2024 · TR · contact PI
A cross-species preclinical platform to enhance the translation of new medicines$832,365
R44 · FY2024 · TR · contact PI
A cross-species preclinical platform to enhance the translation of new medicines$324,648
R44 · FY2023 · TR · contact PI
High-Throughput NMJ Assay for Botox Potency Screening$275,766
U44 · FY2023 · TR · contact PI
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs$169,156
R44 · FY2023 · HL · contact PI
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs$750,000
R44 · FY2022 · HL · contact PI
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs$242,088
R44 · FY2022 · HL · contact PI
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs$123,144
R44 · FY2022 · HL · contact PI
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs$750,000
R44 · FY2021 · HL · contact PI
Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing$745,488
R44 · FY2021 · HL · contact PI
Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing$179,200
R44 · FY2021 · HL · contact PI
Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing$69,068
R44 · FY2021 · HL · contact PI
Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing$750,000
R44 · FY2020 · HL · contact PI
Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs$225,000
R44 · FY2020 · HL · contact PI
High-throughput nanoMEA-based Proarrhythmia Assay$747,868
R44 · FY2019 · HL · contact PI
Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing$225,000
R44 · FY2019 · HL · contact PI
A Combinatorial Bioreactor for Electromechanical Conditioning of Differentiated Stem Cells$225,000
R43 · FY2019 · HL · contact PI
Multiplexed quantitative measurements of field potential and contractility on biomimetically-matured hPSC-CMs$225,000
R43 · FY2019 · EB · contact PI
Low-cost, Roll-to-Roll Manufacturing of Nanoscale Biomimetic Scaffolds for Enhanced Biological Cell Culture$221,713
R43 · FY2019 · EB · contact PI
High-throughput nanoMEA-based Proarrhythmia Assay$129,050
R44 · FY2019 · HL · contact PI
High-throughput nanoMEA-based Proarrhythmia Assay$123,510
R44 · FY2019 · HL · contact PI
High-throughput nanoMEA-based Proarrhythmia Assay$748,435
R44 · FY2018 · HL · contact PI
A Nanopatterned Interdigitated Electrode Array Device for Anti-migratory Cancer Drug Screening$225,000
R43 · FY2017 · CA · contact PI